COMPARATIVE ANALYSIS OF CHANGES IN THE REFERENCE VALUES OF MEDICINAL PRODUCTS INCLUDED IN ANNEX No. 2 TO POSITIVE DRUG LIST IN BULGARIA

The Positive Drug List introduces the first rules for including drugs in the payment system with public funds in Bulgaria. In order to be able to allocate limited budgetary resources in the most effective and fair way and according to the profitability of new drugs,the regulatory institutions that are responsible for pricing and inclusion of drugs for payment with public funds have the greatest need for pharmacoeconomic evaluations. For medicinal products included in the Positive Drug List, the National Health Insurance Fund negotiates with the holders of the authorizations for use or with their authorized representatives discounts on the packaging value. The purpose of the survey is to study and analyze the changes made in the reference values of the medicinal products included in Annex No. 2 to Positive Drug List in Bulgaria for the period 2016-2020. The analysis of the data shows a significant increase in the costs for the National Health Insurance Fund, based on reports, for medicinal products used in the treatment of diseases in the conditions of hospital medical care, included in the study application.